GLP-1 drugmakers sued over sudden vision loss risk: Reports
Dozens of plaintiffs say the drugs caused NAION, and one study found 35 cases among more than 159,000 patients.
- Dozens of patients have filed Lawsuits against drugmakers Novo and Eli Lilly, alleging the companies failed to warn users about sudden vision loss from GLP-1s including Ozempic, Wegovy, Mounjaro, and Zepbound.
- Non-Arteritic anterior ischaemic optic neuropathy, or NAION, is a rare condition that can lead to sudden and sometimes permanent vision loss due to lack of blood flow to the optic nerve.
- Research involving more than 159,000 participants with type 2 diabetes found 35 cases of NAION among GLP-1 users compared to 19 in the comparison group; researchers also identified 93 patients with 'Other optic nerve disorders.'
- Similar Lawsuits against Eli Lilly are currently pending, with plaintiffs claiming the company failed to adequately warn patients of risks associated with their weight-loss and diabetes treatments.
- The American Academy of Ophthalmology encourages clinicians and patients to make 'informed choices' regarding GLP-1s, while noting that studies show modest risk but fewer patients experienced sight-threatening complications from diabetes.
38 Articles
38 Articles
GLP-1 Drugmakers Face Lawsuits as Patients Claim Ozempic and Wegovy Led To Rare Permanent Vision Loss
Hundreds of lawsuits against Novo Nordisk and Eli Lilly allege their GLP-1 drugs caused NAION, a rare eye condition associated with sudden, potentially permanent vision loss.
Lawsuits raise questions about possible GLP-1 link to rare vision loss
(NBC)- A rare eye condition that can cause sudden and potentially permanent vision loss is at the center of lawsuits involving popular GLP-1 medications used for weight loss and diabetes. The condition, known as non-arteritic anterior ischemic optic neuropathy, or NAION, can cause sudden vision loss and has no known treatment. Diane Wirth said she experienced the condition after taking...
Why Are Ozempic, Wegovy and Mounjaro Lawsuits Claiming Rare Vision Loss?
Lawsuits claim GLP-1 drugs like Ozempic, Wegovy, and Mounjaro lack warnings for rare permanent vision loss (NAION), which manufacturers deny as meritless or as being under routine safety monitoring. While studies show mixed correlation and unproven causation, doctors stress heavy metabolic benefits and advise consulting physicians rather than stopping treatment unsupervised. Why Are Ozempic, Wegovy and Mounjaro Lawsuits Claiming Rare Vision Loss…
Coverage Details
Bias Distribution
- 85% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
